SVB Leerink Maintains Outperform on Innate Pharma, Raises Price Target to $9
SVB Leerink analyst Daina Graybosch maintains Innate Pharma (NASDAQ:IPHA) with a Outperform and raises the price target from $7 to $9.
26 Stocks Moving in Wednesday’s Pre-Market Session
Gainers
Nxt-ID, Inc. (NASDAQ: NXTD) rose 46.1% to $0.6699 in pre-market trading after dropping 11% on Tuesday.
Earnings Scheduled For September 15, 2021
Companies Reporting Before The Bell
• Innate Pharma (NASDAQ:IPHA) is expected to report earnings for its first quarter.
45 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
IronNet, Inc. (NYSE: IRNT) shares jumped 50.4% to $25.06 after jumping over 23% on Friday.
